For their epidermal growth factor receptor (EGFR) tyrosine kinase activity, triazole-substituted quinazoline derivatives have been produced and have shown modest activity in tumor cell lines (HCT116, MCF-7, and PC-3) [90]. This evidence concerns the gene EGFR and neoplasm.